<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35363114</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy.</ArticleTitle>
        <Pagination>
          <StartPage>1025</StartPage>
          <EndPage>1037</EndPage>
          <MedlinePgn>1025-1037</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2057616</ELocationID>
        <Abstract>
          <AbstractText>Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, which is characterized by synovial inflammation and autoimmunity. The main cause of the disease is the imbalance of the proportion of pro-inflammatory macrophages (M1-type) and anti-inflammatory macrophages (M2-type) in the synovial tissues of the joint. To restore this balance, in our study, the interleukin-10 encoding anti-inflammatory cytokines (IL-10 pDNA) and chemotherapeutic drug dexamethasone sodium phosphate (DSP) were co-loaded into human serum albumin (HSA) preparing pDNA/DSP-NPs to actively target macrophages in synovium tissue to promote M1-M2 polarization. Confocal laser scanning microscope and western blot were used to demonstrate the targeting ability of co-delivery nanoparticles. <i>In vivo</i>, the real-time fluorescence imaging system and HPLC were used to study the tissue distribution and pharmacokinetics of nanoparticles, and the results showed that the accumulation of nanoparticles in the inflammatory joint site was higher. Its pharmacodynamics were evaluated in collagen-induced arthritis (CIA) rat model, and it demonstrated that the pDNA/DSP-NPs significantly reduced the expression of serum inflammatory factors and alleviated joint swelling and bone erosion, suggesting the favorable therapeutic effect. The synergistic treatment effect of IL-10 pDNA and DSP in this system was achieved by reducing the secretion of pro-inflammatory factors (TNF-α, IL-1β) and increasing the expression of anti-inflammatory factors (IL-10) to promote the M1-M2 polarization of macrophages. Our strategy is promising for co-delivery of gene drugs and chemical drugs by biomimetic natural materials to promote macrophages polarization so that to achieve synergically treatment of inflammatory disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xiu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Chinese Pharmacy laboratory, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chenglong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Fenting</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ji</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chunhong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001169" MajorTopicYN="Y">Arthritis, Experimental</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>
        <Keyword MajorTopicYN="N">biomimetic</Keyword>
        <Keyword MajorTopicYN="N">human serum albumin</Keyword>
        <Keyword MajorTopicYN="N">macrophage polarization</Keyword>
        <Keyword MajorTopicYN="N">synergistic effect</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35363114</ArticleId>
        <ArticleId IdType="pmc">PMC8979516</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2057616</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Barnes PJ. (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond)
94:557–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9854452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baschant U, Lane NE, Tuckermann J. (2012). The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat Rev Rheumatol
8:645–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23045254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanco E, Shen H, Ferrari M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol
33:941–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4978509</ArticleId>
            <ArticleId IdType="pubmed">26348965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brand
DD, , Latham
KA, , Rosloniec EF. (2007). Collagen-induced arthritis. Nat Protoc
2:1269–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17546023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briggs J, Chamboredon S, Castellazzi M, et al.  (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene
21:7077–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12370830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo P, Kolls JK. (2016). IL-10: a paradigm for counterregulatory cytokines. J Immunol
197:1529–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27543665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Chen J, Liang C, et al.  (2017). Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy. J Controlled Release
263:79–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27840167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Wang RT, Wang Z, et al.  (2010). Construction and evaluation of non-specific targeting cationic polymer lipid liposomes. Yao Xue Xue Bao
45:359–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21351513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crielaard BJ, Rijcken CJ, Quan L, et al.  (2012). Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem Int Ed Engl
51:7254–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3499037</ArticleId>
            <ArticleId IdType="pubmed">22692876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degboé Y, Rauwel B, Baron M, et al.  (2019). Polarization of rheumatoid macrophages by TNF targeting through an IL-10/STAT3 mechanism. Front Immunol
10:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6345709</ArticleId>
            <ArticleId IdType="pubmed">30713533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derosa CA, Furusato B, Shaheduzzaman S, et al.  (2012). Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis
15:150–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22343836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fickenscher H, Hör S, Küpers H, et al.  (2002). The interleukin-10 family of cytokines. Trends Immunol
23:89–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11929132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fosgerau K, Hoffmann T. (2015). Peptide therapeutics: current status and future directions. Drug Discov Today
20:122–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ip WKE, Hoshi N, Shouval DS, et al.  (2017). Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science
356:513–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6260791</ArticleId>
            <ArticleId IdType="pubmed">28473584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain S, Tran TH, Amiji M. (2015). Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials
61:162–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4464978</ArticleId>
            <ArticleId IdType="pubmed">26004232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karami E, Behdani M, Kazemi-Lomedasht F. (2020). Albumin nanoparticles as nanocarriers for drug delivery: focusing on antibody and nanobody delivery and albumin-based drugs. J Drug Delivery Sci Technol
55:101471.</Citation>
        </Reference>
        <Reference>
          <Citation>Li H, Feng Y, Zheng X, et al.  (2022). M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization. J Control Release
341:16–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34793917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Chen L, Xu X, et al.  (2020). Targeted combination of antioxidative and anti-inflammatory therapy of rheumatoid arthritis using multifunctional dendrimer-entrapped gold nanoparticles as a platform. Small
16:2005661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33205596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Xie J, Niu G, et al.  (2011). Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett
11:814–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3036786</ArticleId>
            <ArticleId IdType="pubmed">21210706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Hu F, Wang H, et al.  (2019). Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy. ACS Nano
13:5036–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30978282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Look J, Wilhelm N, von Briesen H, et al.  (2015). Ligand-modified human serum albumin nanoparticles for enhanced gene delivery. Mol Pharm
12:3202–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26218774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyu J, Wang L, Bai X, et al.  (2021). Treatment of rheumatoid arthritis by serum albumin nanoparticles coated with mannose to target neutrophils. ACS Appl Mater Interfaces
13:266–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33379867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi FL, Burnouf T, Lu SY, et al.  (2017). Self-targeting, immune transparent plasma protein coated nanocomplex for noninvasive photothermal anticancer therapy. Adv Healthcare Mater
6:1700181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28722819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosser DM, Zhang X. (2008). Interleukin-10: new perspectives on an old cytokine. Immunol Rev
226:205–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2724982</ArticleId>
            <ArticleId IdType="pubmed">19161426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oray M, Abu Samra K, Ebrahimiadib N, et al.  (2016). Long-term side effects of glucocorticoids. Expert Opin Drug Saf
15:457–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26789102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandey S, Mahtab A, Rai N, et al.  (2017). Emerging role of CD44 receptor as a potential target in disease diagnosis: a patent review. Recent Pat Inflamm Allergy Drug Discov
11:77–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28891438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel HM, Moghimi SM. (1998). Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - the concept of tissue specificity. Adv Drug Deliv Rev
32:45–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10837635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quan
L, Zhang
Y, Dusad A, et al. .  (2016). The evaluation of the therapeutic efficacy and side effects of a macromolecular dexamethasone prodrug in the collagen-induced arthritis mouse model. Pharm Res
33:186–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4690754</ArticleId>
            <ArticleId IdType="pubmed">26286188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rall LC, Rosen CJ, Dolnikowski G, et al.  (1996). Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. Arthritis Rheum
39:1115–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8670319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren H, He Y, Liang J, et al.  (2019). Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy. ACS Appl Mater Interfaces
11:20304–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31056910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparks JA. (2019). Rheumatoid arthritis. Ann Intern Med
170:ITC1–itc16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30596879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan T, Huang Q, Chu W, et al.  (2022). Delivery of germacrone (GER) using macrophages-targeted polymeric nanoparticles and its application in rheumatoid arthritis. Drug Deliv
29:692–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8890522</ArticleId>
            <ArticleId IdType="pubmed">35225122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng MW, Darcy PK, Smyth MJ. (2011). Stable IL-10: a new therapeutic that promotes tumor immunity. Cancer Cell
20:691–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22172716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian L, Chen Q, Yi X, et al.  (2017). Radionuclide I-131 labeled albumin-paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of cancer. Theranostics
7:614–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5327637</ArticleId>
            <ArticleId IdType="pubmed">28255354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Woude D, van der Helm-van Mil AHM. (2018). Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol
32:174–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30527425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandewalle J, Luypaert A, De Bosscher K, et al.  (2018). Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab
29:42–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29162310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Jiang J, Chen W, et al.  (2016). Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis. J Control Release
230:64–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27057749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Sun X. (2017). Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci
5:1407–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28631779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Smith W, Hao D, et al.  (2019). M1 and M2 macrophage polarization and potentially therapeutic naturally occurring compounds. Int Immunopharmacol
70:459–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30861466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei
X, Wu
J, Zhao G, et al. .  (2018). Development of a janus kinase inhibitor prodrug for the treatment of rheumatoid arthritis. Mol Pharm
15:3456–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6078779</ArticleId>
            <ArticleId IdType="pubmed">29966420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan F, Li H, Zhong Z, et al.  (2019). Co-delivery of prednisolone and curcumin in human serum albumin nanoparticles for effective treatment of rheumatoid arthritis. Int J Nanomedicine
14:9113–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6878998</ArticleId>
            <ArticleId IdType="pubmed">31819422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao P, Wang Y, Wu A, et al.  (2018). Roles of albumin-binding proteins in cancer progression and biomimetic targeted drug delivery. Chembiochem
19:1796–805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29920893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong J, Zhang Q, Zhang Z, et al.  (2022). Albumin mediated reactive oxygen species scavenging and targeted delivery of methotrexate for rheumatoid arthritis therapy. Nano Res
15:153–61.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35363114</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy.</ArticleTitle>
        <Pagination>
          <StartPage>1025</StartPage>
          <EndPage>1037</EndPage>
          <MedlinePgn>1025-1037</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2057616</ELocationID>
        <Abstract>
          <AbstractText>Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, which is characterized by synovial inflammation and autoimmunity. The main cause of the disease is the imbalance of the proportion of pro-inflammatory macrophages (M1-type) and anti-inflammatory macrophages (M2-type) in the synovial tissues of the joint. To restore this balance, in our study, the interleukin-10 encoding anti-inflammatory cytokines (IL-10 pDNA) and chemotherapeutic drug dexamethasone sodium phosphate (DSP) were co-loaded into human serum albumin (HSA) preparing pDNA/DSP-NPs to actively target macrophages in synovium tissue to promote M1-M2 polarization. Confocal laser scanning microscope and western blot were used to demonstrate the targeting ability of co-delivery nanoparticles. <i>In vivo</i>, the real-time fluorescence imaging system and HPLC were used to study the tissue distribution and pharmacokinetics of nanoparticles, and the results showed that the accumulation of nanoparticles in the inflammatory joint site was higher. Its pharmacodynamics were evaluated in collagen-induced arthritis (CIA) rat model, and it demonstrated that the pDNA/DSP-NPs significantly reduced the expression of serum inflammatory factors and alleviated joint swelling and bone erosion, suggesting the favorable therapeutic effect. The synergistic treatment effect of IL-10 pDNA and DSP in this system was achieved by reducing the secretion of pro-inflammatory factors (TNF-α, IL-1β) and increasing the expression of anti-inflammatory factors (IL-10) to promote the M1-M2 polarization of macrophages. Our strategy is promising for co-delivery of gene drugs and chemical drugs by biomimetic natural materials to promote macrophages polarization so that to achieve synergically treatment of inflammatory disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xiu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Chinese Pharmacy laboratory, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chenglong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Fenting</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ji</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chunhong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001169" MajorTopicYN="Y">Arthritis, Experimental</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>
        <Keyword MajorTopicYN="N">biomimetic</Keyword>
        <Keyword MajorTopicYN="N">human serum albumin</Keyword>
        <Keyword MajorTopicYN="N">macrophage polarization</Keyword>
        <Keyword MajorTopicYN="N">synergistic effect</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35363114</ArticleId>
        <ArticleId IdType="pmc">PMC8979516</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2057616</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Barnes PJ. (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond)
94:557–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9854452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baschant U, Lane NE, Tuckermann J. (2012). The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat Rev Rheumatol
8:645–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23045254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanco E, Shen H, Ferrari M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol
33:941–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4978509</ArticleId>
            <ArticleId IdType="pubmed">26348965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brand
DD, , Latham
KA, , Rosloniec EF. (2007). Collagen-induced arthritis. Nat Protoc
2:1269–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17546023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briggs J, Chamboredon S, Castellazzi M, et al.  (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene
21:7077–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12370830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo P, Kolls JK. (2016). IL-10: a paradigm for counterregulatory cytokines. J Immunol
197:1529–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27543665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Chen J, Liang C, et al.  (2017). Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy. J Controlled Release
263:79–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27840167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Wang RT, Wang Z, et al.  (2010). Construction and evaluation of non-specific targeting cationic polymer lipid liposomes. Yao Xue Xue Bao
45:359–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21351513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crielaard BJ, Rijcken CJ, Quan L, et al.  (2012). Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem Int Ed Engl
51:7254–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3499037</ArticleId>
            <ArticleId IdType="pubmed">22692876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degboé Y, Rauwel B, Baron M, et al.  (2019). Polarization of rheumatoid macrophages by TNF targeting through an IL-10/STAT3 mechanism. Front Immunol
10:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6345709</ArticleId>
            <ArticleId IdType="pubmed">30713533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derosa CA, Furusato B, Shaheduzzaman S, et al.  (2012). Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis
15:150–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22343836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fickenscher H, Hör S, Küpers H, et al.  (2002). The interleukin-10 family of cytokines. Trends Immunol
23:89–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11929132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fosgerau K, Hoffmann T. (2015). Peptide therapeutics: current status and future directions. Drug Discov Today
20:122–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ip WKE, Hoshi N, Shouval DS, et al.  (2017). Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science
356:513–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6260791</ArticleId>
            <ArticleId IdType="pubmed">28473584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain S, Tran TH, Amiji M. (2015). Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials
61:162–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4464978</ArticleId>
            <ArticleId IdType="pubmed">26004232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karami E, Behdani M, Kazemi-Lomedasht F. (2020). Albumin nanoparticles as nanocarriers for drug delivery: focusing on antibody and nanobody delivery and albumin-based drugs. J Drug Delivery Sci Technol
55:101471.</Citation>
        </Reference>
        <Reference>
          <Citation>Li H, Feng Y, Zheng X, et al.  (2022). M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization. J Control Release
341:16–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34793917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Chen L, Xu X, et al.  (2020). Targeted combination of antioxidative and anti-inflammatory therapy of rheumatoid arthritis using multifunctional dendrimer-entrapped gold nanoparticles as a platform. Small
16:2005661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33205596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Xie J, Niu G, et al.  (2011). Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett
11:814–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3036786</ArticleId>
            <ArticleId IdType="pubmed">21210706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Hu F, Wang H, et al.  (2019). Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy. ACS Nano
13:5036–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30978282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Look J, Wilhelm N, von Briesen H, et al.  (2015). Ligand-modified human serum albumin nanoparticles for enhanced gene delivery. Mol Pharm
12:3202–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26218774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyu J, Wang L, Bai X, et al.  (2021). Treatment of rheumatoid arthritis by serum albumin nanoparticles coated with mannose to target neutrophils. ACS Appl Mater Interfaces
13:266–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33379867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi FL, Burnouf T, Lu SY, et al.  (2017). Self-targeting, immune transparent plasma protein coated nanocomplex for noninvasive photothermal anticancer therapy. Adv Healthcare Mater
6:1700181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28722819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosser DM, Zhang X. (2008). Interleukin-10: new perspectives on an old cytokine. Immunol Rev
226:205–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2724982</ArticleId>
            <ArticleId IdType="pubmed">19161426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oray M, Abu Samra K, Ebrahimiadib N, et al.  (2016). Long-term side effects of glucocorticoids. Expert Opin Drug Saf
15:457–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26789102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandey S, Mahtab A, Rai N, et al.  (2017). Emerging role of CD44 receptor as a potential target in disease diagnosis: a patent review. Recent Pat Inflamm Allergy Drug Discov
11:77–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28891438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel HM, Moghimi SM. (1998). Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - the concept of tissue specificity. Adv Drug Deliv Rev
32:45–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10837635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quan
L, Zhang
Y, Dusad A, et al. .  (2016). The evaluation of the therapeutic efficacy and side effects of a macromolecular dexamethasone prodrug in the collagen-induced arthritis mouse model. Pharm Res
33:186–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4690754</ArticleId>
            <ArticleId IdType="pubmed">26286188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rall LC, Rosen CJ, Dolnikowski G, et al.  (1996). Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. Arthritis Rheum
39:1115–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8670319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren H, He Y, Liang J, et al.  (2019). Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy. ACS Appl Mater Interfaces
11:20304–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31056910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparks JA. (2019). Rheumatoid arthritis. Ann Intern Med
170:ITC1–itc16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30596879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan T, Huang Q, Chu W, et al.  (2022). Delivery of germacrone (GER) using macrophages-targeted polymeric nanoparticles and its application in rheumatoid arthritis. Drug Deliv
29:692–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8890522</ArticleId>
            <ArticleId IdType="pubmed">35225122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng MW, Darcy PK, Smyth MJ. (2011). Stable IL-10: a new therapeutic that promotes tumor immunity. Cancer Cell
20:691–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22172716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian L, Chen Q, Yi X, et al.  (2017). Radionuclide I-131 labeled albumin-paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of cancer. Theranostics
7:614–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5327637</ArticleId>
            <ArticleId IdType="pubmed">28255354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Woude D, van der Helm-van Mil AHM. (2018). Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol
32:174–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30527425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandewalle J, Luypaert A, De Bosscher K, et al.  (2018). Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab
29:42–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29162310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Jiang J, Chen W, et al.  (2016). Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis. J Control Release
230:64–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27057749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Sun X. (2017). Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci
5:1407–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28631779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Smith W, Hao D, et al.  (2019). M1 and M2 macrophage polarization and potentially therapeutic naturally occurring compounds. Int Immunopharmacol
70:459–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30861466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei
X, Wu
J, Zhao G, et al. .  (2018). Development of a janus kinase inhibitor prodrug for the treatment of rheumatoid arthritis. Mol Pharm
15:3456–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6078779</ArticleId>
            <ArticleId IdType="pubmed">29966420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan F, Li H, Zhong Z, et al.  (2019). Co-delivery of prednisolone and curcumin in human serum albumin nanoparticles for effective treatment of rheumatoid arthritis. Int J Nanomedicine
14:9113–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6878998</ArticleId>
            <ArticleId IdType="pubmed">31819422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao P, Wang Y, Wu A, et al.  (2018). Roles of albumin-binding proteins in cancer progression and biomimetic targeted drug delivery. Chembiochem
19:1796–805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29920893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong J, Zhang Q, Zhang Z, et al.  (2022). Albumin mediated reactive oxygen species scavenging and targeted delivery of methotrexate for rheumatoid arthritis therapy. Nano Res
15:153–61.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35363114</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy.</ArticleTitle>
        <Pagination>
          <StartPage>1025</StartPage>
          <EndPage>1037</EndPage>
          <MedlinePgn>1025-1037</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2057616</ELocationID>
        <Abstract>
          <AbstractText>Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, which is characterized by synovial inflammation and autoimmunity. The main cause of the disease is the imbalance of the proportion of pro-inflammatory macrophages (M1-type) and anti-inflammatory macrophages (M2-type) in the synovial tissues of the joint. To restore this balance, in our study, the interleukin-10 encoding anti-inflammatory cytokines (IL-10 pDNA) and chemotherapeutic drug dexamethasone sodium phosphate (DSP) were co-loaded into human serum albumin (HSA) preparing pDNA/DSP-NPs to actively target macrophages in synovium tissue to promote M1-M2 polarization. Confocal laser scanning microscope and western blot were used to demonstrate the targeting ability of co-delivery nanoparticles. <i>In vivo</i>, the real-time fluorescence imaging system and HPLC were used to study the tissue distribution and pharmacokinetics of nanoparticles, and the results showed that the accumulation of nanoparticles in the inflammatory joint site was higher. Its pharmacodynamics were evaluated in collagen-induced arthritis (CIA) rat model, and it demonstrated that the pDNA/DSP-NPs significantly reduced the expression of serum inflammatory factors and alleviated joint swelling and bone erosion, suggesting the favorable therapeutic effect. The synergistic treatment effect of IL-10 pDNA and DSP in this system was achieved by reducing the secretion of pro-inflammatory factors (TNF-α, IL-1β) and increasing the expression of anti-inflammatory factors (IL-10) to promote the M1-M2 polarization of macrophages. Our strategy is promising for co-delivery of gene drugs and chemical drugs by biomimetic natural materials to promote macrophages polarization so that to achieve synergically treatment of inflammatory disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xiu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Chinese Pharmacy laboratory, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chenglong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Fenting</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ji</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chunhong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001169" MajorTopicYN="Y">Arthritis, Experimental</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>
        <Keyword MajorTopicYN="N">biomimetic</Keyword>
        <Keyword MajorTopicYN="N">human serum albumin</Keyword>
        <Keyword MajorTopicYN="N">macrophage polarization</Keyword>
        <Keyword MajorTopicYN="N">synergistic effect</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35363114</ArticleId>
        <ArticleId IdType="pmc">PMC8979516</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2057616</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Barnes PJ. (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond)
94:557–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9854452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baschant U, Lane NE, Tuckermann J. (2012). The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat Rev Rheumatol
8:645–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23045254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanco E, Shen H, Ferrari M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol
33:941–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4978509</ArticleId>
            <ArticleId IdType="pubmed">26348965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brand
DD, , Latham
KA, , Rosloniec EF. (2007). Collagen-induced arthritis. Nat Protoc
2:1269–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17546023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briggs J, Chamboredon S, Castellazzi M, et al.  (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene
21:7077–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12370830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo P, Kolls JK. (2016). IL-10: a paradigm for counterregulatory cytokines. J Immunol
197:1529–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27543665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Chen J, Liang C, et al.  (2017). Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy. J Controlled Release
263:79–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27840167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Wang RT, Wang Z, et al.  (2010). Construction and evaluation of non-specific targeting cationic polymer lipid liposomes. Yao Xue Xue Bao
45:359–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21351513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crielaard BJ, Rijcken CJ, Quan L, et al.  (2012). Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem Int Ed Engl
51:7254–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3499037</ArticleId>
            <ArticleId IdType="pubmed">22692876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degboé Y, Rauwel B, Baron M, et al.  (2019). Polarization of rheumatoid macrophages by TNF targeting through an IL-10/STAT3 mechanism. Front Immunol
10:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6345709</ArticleId>
            <ArticleId IdType="pubmed">30713533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derosa CA, Furusato B, Shaheduzzaman S, et al.  (2012). Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis
15:150–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22343836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fickenscher H, Hör S, Küpers H, et al.  (2002). The interleukin-10 family of cytokines. Trends Immunol
23:89–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11929132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fosgerau K, Hoffmann T. (2015). Peptide therapeutics: current status and future directions. Drug Discov Today
20:122–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ip WKE, Hoshi N, Shouval DS, et al.  (2017). Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science
356:513–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6260791</ArticleId>
            <ArticleId IdType="pubmed">28473584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain S, Tran TH, Amiji M. (2015). Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials
61:162–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4464978</ArticleId>
            <ArticleId IdType="pubmed">26004232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karami E, Behdani M, Kazemi-Lomedasht F. (2020). Albumin nanoparticles as nanocarriers for drug delivery: focusing on antibody and nanobody delivery and albumin-based drugs. J Drug Delivery Sci Technol
55:101471.</Citation>
        </Reference>
        <Reference>
          <Citation>Li H, Feng Y, Zheng X, et al.  (2022). M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization. J Control Release
341:16–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34793917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Chen L, Xu X, et al.  (2020). Targeted combination of antioxidative and anti-inflammatory therapy of rheumatoid arthritis using multifunctional dendrimer-entrapped gold nanoparticles as a platform. Small
16:2005661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33205596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Xie J, Niu G, et al.  (2011). Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett
11:814–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3036786</ArticleId>
            <ArticleId IdType="pubmed">21210706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Hu F, Wang H, et al.  (2019). Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy. ACS Nano
13:5036–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30978282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Look J, Wilhelm N, von Briesen H, et al.  (2015). Ligand-modified human serum albumin nanoparticles for enhanced gene delivery. Mol Pharm
12:3202–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26218774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyu J, Wang L, Bai X, et al.  (2021). Treatment of rheumatoid arthritis by serum albumin nanoparticles coated with mannose to target neutrophils. ACS Appl Mater Interfaces
13:266–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33379867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi FL, Burnouf T, Lu SY, et al.  (2017). Self-targeting, immune transparent plasma protein coated nanocomplex for noninvasive photothermal anticancer therapy. Adv Healthcare Mater
6:1700181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28722819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosser DM, Zhang X. (2008). Interleukin-10: new perspectives on an old cytokine. Immunol Rev
226:205–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2724982</ArticleId>
            <ArticleId IdType="pubmed">19161426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oray M, Abu Samra K, Ebrahimiadib N, et al.  (2016). Long-term side effects of glucocorticoids. Expert Opin Drug Saf
15:457–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26789102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandey S, Mahtab A, Rai N, et al.  (2017). Emerging role of CD44 receptor as a potential target in disease diagnosis: a patent review. Recent Pat Inflamm Allergy Drug Discov
11:77–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28891438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel HM, Moghimi SM. (1998). Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - the concept of tissue specificity. Adv Drug Deliv Rev
32:45–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10837635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quan
L, Zhang
Y, Dusad A, et al. .  (2016). The evaluation of the therapeutic efficacy and side effects of a macromolecular dexamethasone prodrug in the collagen-induced arthritis mouse model. Pharm Res
33:186–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4690754</ArticleId>
            <ArticleId IdType="pubmed">26286188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rall LC, Rosen CJ, Dolnikowski G, et al.  (1996). Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. Arthritis Rheum
39:1115–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8670319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren H, He Y, Liang J, et al.  (2019). Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy. ACS Appl Mater Interfaces
11:20304–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31056910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparks JA. (2019). Rheumatoid arthritis. Ann Intern Med
170:ITC1–itc16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30596879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan T, Huang Q, Chu W, et al.  (2022). Delivery of germacrone (GER) using macrophages-targeted polymeric nanoparticles and its application in rheumatoid arthritis. Drug Deliv
29:692–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8890522</ArticleId>
            <ArticleId IdType="pubmed">35225122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng MW, Darcy PK, Smyth MJ. (2011). Stable IL-10: a new therapeutic that promotes tumor immunity. Cancer Cell
20:691–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22172716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian L, Chen Q, Yi X, et al.  (2017). Radionuclide I-131 labeled albumin-paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of cancer. Theranostics
7:614–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5327637</ArticleId>
            <ArticleId IdType="pubmed">28255354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Woude D, van der Helm-van Mil AHM. (2018). Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol
32:174–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30527425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandewalle J, Luypaert A, De Bosscher K, et al.  (2018). Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab
29:42–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29162310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Jiang J, Chen W, et al.  (2016). Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis. J Control Release
230:64–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27057749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Sun X. (2017). Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci
5:1407–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28631779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Smith W, Hao D, et al.  (2019). M1 and M2 macrophage polarization and potentially therapeutic naturally occurring compounds. Int Immunopharmacol
70:459–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30861466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei
X, Wu
J, Zhao G, et al. .  (2018). Development of a janus kinase inhibitor prodrug for the treatment of rheumatoid arthritis. Mol Pharm
15:3456–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6078779</ArticleId>
            <ArticleId IdType="pubmed">29966420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan F, Li H, Zhong Z, et al.  (2019). Co-delivery of prednisolone and curcumin in human serum albumin nanoparticles for effective treatment of rheumatoid arthritis. Int J Nanomedicine
14:9113–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6878998</ArticleId>
            <ArticleId IdType="pubmed">31819422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao P, Wang Y, Wu A, et al.  (2018). Roles of albumin-binding proteins in cancer progression and biomimetic targeted drug delivery. Chembiochem
19:1796–805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29920893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong J, Zhang Q, Zhang Z, et al.  (2022). Albumin mediated reactive oxygen species scavenging and targeted delivery of methotrexate for rheumatoid arthritis therapy. Nano Res
15:153–61.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35363114</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy.</ArticleTitle>
        <Pagination>
          <StartPage>1025</StartPage>
          <EndPage>1037</EndPage>
          <MedlinePgn>1025-1037</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2057616</ELocationID>
        <Abstract>
          <AbstractText>Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, which is characterized by synovial inflammation and autoimmunity. The main cause of the disease is the imbalance of the proportion of pro-inflammatory macrophages (M1-type) and anti-inflammatory macrophages (M2-type) in the synovial tissues of the joint. To restore this balance, in our study, the interleukin-10 encoding anti-inflammatory cytokines (IL-10 pDNA) and chemotherapeutic drug dexamethasone sodium phosphate (DSP) were co-loaded into human serum albumin (HSA) preparing pDNA/DSP-NPs to actively target macrophages in synovium tissue to promote M1-M2 polarization. Confocal laser scanning microscope and western blot were used to demonstrate the targeting ability of co-delivery nanoparticles. <i>In vivo</i>, the real-time fluorescence imaging system and HPLC were used to study the tissue distribution and pharmacokinetics of nanoparticles, and the results showed that the accumulation of nanoparticles in the inflammatory joint site was higher. Its pharmacodynamics were evaluated in collagen-induced arthritis (CIA) rat model, and it demonstrated that the pDNA/DSP-NPs significantly reduced the expression of serum inflammatory factors and alleviated joint swelling and bone erosion, suggesting the favorable therapeutic effect. The synergistic treatment effect of IL-10 pDNA and DSP in this system was achieved by reducing the secretion of pro-inflammatory factors (TNF-α, IL-1β) and increasing the expression of anti-inflammatory factors (IL-10) to promote the M1-M2 polarization of macrophages. Our strategy is promising for co-delivery of gene drugs and chemical drugs by biomimetic natural materials to promote macrophages polarization so that to achieve synergically treatment of inflammatory disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Xiu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Chinese Pharmacy laboratory, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chenglong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lei</LastName>
            <ForeName>Fenting</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Ji</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Analysis and Testing Center, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Chunhong</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001169" MajorTopicYN="Y">Arthritis, Experimental</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032701" MajorTopicYN="N">Biomimetics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword>
        <Keyword MajorTopicYN="N">biomimetic</Keyword>
        <Keyword MajorTopicYN="N">human serum albumin</Keyword>
        <Keyword MajorTopicYN="N">macrophage polarization</Keyword>
        <Keyword MajorTopicYN="N">synergistic effect</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35363114</ArticleId>
        <ArticleId IdType="pmc">PMC8979516</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2057616</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Barnes PJ. (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond)
94:557–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9854452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baschant U, Lane NE, Tuckermann J. (2012). The multiple facets of glucocorticoid action in rheumatoid arthritis. Nat Rev Rheumatol
8:645–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23045254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Blanco E, Shen H, Ferrari M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol
33:941–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4978509</ArticleId>
            <ArticleId IdType="pubmed">26348965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brand
DD, , Latham
KA, , Rosloniec EF. (2007). Collagen-induced arthritis. Nat Protoc
2:1269–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17546023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Briggs J, Chamboredon S, Castellazzi M, et al.  (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene
21:7077–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12370830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo P, Kolls JK. (2016). IL-10: a paradigm for counterregulatory cytokines. J Immunol
197:1529–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27543665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Chen J, Liang C, et al.  (2017). Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy. J Controlled Release
263:79–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27840167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Wang RT, Wang Z, et al.  (2010). Construction and evaluation of non-specific targeting cationic polymer lipid liposomes. Yao Xue Xue Bao
45:359–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21351513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crielaard BJ, Rijcken CJ, Quan L, et al.  (2012). Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. Angew Chem Int Ed Engl
51:7254–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3499037</ArticleId>
            <ArticleId IdType="pubmed">22692876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Degboé Y, Rauwel B, Baron M, et al.  (2019). Polarization of rheumatoid macrophages by TNF targeting through an IL-10/STAT3 mechanism. Front Immunol
10:3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6345709</ArticleId>
            <ArticleId IdType="pubmed">30713533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derosa CA, Furusato B, Shaheduzzaman S, et al.  (2012). Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis
15:150–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22343836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fickenscher H, Hör S, Küpers H, et al.  (2002). The interleukin-10 family of cytokines. Trends Immunol
23:89–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11929132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fosgerau K, Hoffmann T. (2015). Peptide therapeutics: current status and future directions. Drug Discov Today
20:122–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25450771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ip WKE, Hoshi N, Shouval DS, et al.  (2017). Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science
356:513–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6260791</ArticleId>
            <ArticleId IdType="pubmed">28473584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain S, Tran TH, Amiji M. (2015). Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis. Biomaterials
61:162–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4464978</ArticleId>
            <ArticleId IdType="pubmed">26004232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karami E, Behdani M, Kazemi-Lomedasht F. (2020). Albumin nanoparticles as nanocarriers for drug delivery: focusing on antibody and nanobody delivery and albumin-based drugs. J Drug Delivery Sci Technol
55:101471.</Citation>
        </Reference>
        <Reference>
          <Citation>Li H, Feng Y, Zheng X, et al.  (2022). M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization. J Control Release
341:16–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34793917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Chen L, Xu X, et al.  (2020). Targeted combination of antioxidative and anti-inflammatory therapy of rheumatoid arthritis using multifunctional dendrimer-entrapped gold nanoparticles as a platform. Small
16:2005661.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33205596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin X, Xie J, Niu G, et al.  (2011). Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett
11:814–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3036786</ArticleId>
            <ArticleId IdType="pubmed">21210706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L, Hu F, Wang H, et al.  (2019). Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy. ACS Nano
13:5036–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30978282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Look J, Wilhelm N, von Briesen H, et al.  (2015). Ligand-modified human serum albumin nanoparticles for enhanced gene delivery. Mol Pharm
12:3202–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26218774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lyu J, Wang L, Bai X, et al.  (2021). Treatment of rheumatoid arthritis by serum albumin nanoparticles coated with mannose to target neutrophils. ACS Appl Mater Interfaces
13:266–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33379867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi FL, Burnouf T, Lu SY, et al.  (2017). Self-targeting, immune transparent plasma protein coated nanocomplex for noninvasive photothermal anticancer therapy. Adv Healthcare Mater
6:1700181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28722819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosser DM, Zhang X. (2008). Interleukin-10: new perspectives on an old cytokine. Immunol Rev
226:205–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2724982</ArticleId>
            <ArticleId IdType="pubmed">19161426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oray M, Abu Samra K, Ebrahimiadib N, et al.  (2016). Long-term side effects of glucocorticoids. Expert Opin Drug Saf
15:457–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26789102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandey S, Mahtab A, Rai N, et al.  (2017). Emerging role of CD44 receptor as a potential target in disease diagnosis: a patent review. Recent Pat Inflamm Allergy Drug Discov
11:77–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28891438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel HM, Moghimi SM. (1998). Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - the concept of tissue specificity. Adv Drug Deliv Rev
32:45–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10837635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quan
L, Zhang
Y, Dusad A, et al. .  (2016). The evaluation of the therapeutic efficacy and side effects of a macromolecular dexamethasone prodrug in the collagen-induced arthritis mouse model. Pharm Res
33:186–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4690754</ArticleId>
            <ArticleId IdType="pubmed">26286188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rall LC, Rosen CJ, Dolnikowski G, et al.  (1996). Protein metabolism in rheumatoid arthritis and aging. Effects of muscle strength training and tumor necrosis factor alpha. Arthritis Rheum
39:1115–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8670319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren H, He Y, Liang J, et al.  (2019). Role of liposome size, surface charge, and PEGylation on rheumatoid arthritis targeting therapy. ACS Appl Mater Interfaces
11:20304–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31056910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparks JA. (2019). Rheumatoid arthritis. Ann Intern Med
170:ITC1–itc16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30596879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan T, Huang Q, Chu W, et al.  (2022). Delivery of germacrone (GER) using macrophages-targeted polymeric nanoparticles and its application in rheumatoid arthritis. Drug Deliv
29:692–701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8890522</ArticleId>
            <ArticleId IdType="pubmed">35225122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teng MW, Darcy PK, Smyth MJ. (2011). Stable IL-10: a new therapeutic that promotes tumor immunity. Cancer Cell
20:691–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22172716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian L, Chen Q, Yi X, et al.  (2017). Radionuclide I-131 labeled albumin-paclitaxel nanoparticles for synergistic combined chemo-radioisotope therapy of cancer. Theranostics
7:614–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5327637</ArticleId>
            <ArticleId IdType="pubmed">28255354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Woude D, van der Helm-van Mil AHM. (2018). Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol
32:174–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30527425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vandewalle J, Luypaert A, De Bosscher K, et al.  (2018). Therapeutic mechanisms of glucocorticoids. Trends Endocrinol Metab
29:42–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29162310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Jiang J, Chen W, et al.  (2016). Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis. J Control Release
230:64–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27057749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Q, Sun X. (2017). Recent advances in nanomedicines for the treatment of rheumatoid arthritis. Biomater Sci
5:1407–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28631779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Smith W, Hao D, et al.  (2019). M1 and M2 macrophage polarization and potentially therapeutic naturally occurring compounds. Int Immunopharmacol
70:459–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30861466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei
X, Wu
J, Zhao G, et al. .  (2018). Development of a janus kinase inhibitor prodrug for the treatment of rheumatoid arthritis. Mol Pharm
15:3456–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6078779</ArticleId>
            <ArticleId IdType="pubmed">29966420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan F, Li H, Zhong Z, et al.  (2019). Co-delivery of prednisolone and curcumin in human serum albumin nanoparticles for effective treatment of rheumatoid arthritis. Int J Nanomedicine
14:9113–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6878998</ArticleId>
            <ArticleId IdType="pubmed">31819422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao P, Wang Y, Wu A, et al.  (2018). Roles of albumin-binding proteins in cancer progression and biomimetic targeted drug delivery. Chembiochem
19:1796–805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29920893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong J, Zhang Q, Zhang Z, et al.  (2022). Albumin mediated reactive oxygen species scavenging and targeted delivery of methotrexate for rheumatoid arthritis therapy. Nano Res
15:153–61.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
